| Assessment Status |
Pre-submission consultation scheduled |
| HTA ID |
26022 |
| Drug |
Toripalimab |
| Brand |
Loqtorzi® |
| Indication |
Toripalimab (Loqtorzi®) in combination with cisplatin and gemcitabine is indicated for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma. |
| Rapid review commissioned |
12/05/2026 |
| Rapid review completed |
09/06/2026 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of toripalimab (Loqtorzi®) compared with the current standard of care. |
| Full HTA commissioned by the HSE |
10/06/2026 |
